Aim: Both attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) are frequently accompanied by serious aggression that requires psychiatric treatment. However, little is known about the experiences psychiatrists have had using pharmacotherapy to treat aggression in patients who have both ASD and ADHD (ASD/ADHD). The purpose of this study was to examine the experiences of Japanese child and adolescent psychiatrists in prescribing medication for aggression in patients with ASD/ADHD.
A GGRESSION IS A common yet complex behavioral complaint, and a frequent indication of a need for treatment by a child or adolescent psychiatrist. It is not a criterion for a diagnosis of attention-deficit hyperactivity disorder (ADHD), 1, 2 but it is often prominent in the clinical presentation of ADHD and often motivates initial referral for mental health evaluation. 3 Indeed, 54% of children with ADHD have clinically significant aggression. 2 Moreover, aggression may have a much greater impact on impairment in daily life than ADHD symptoms alone. Adjunctive therapy with an aggression-targeting agent is recommended when aggressive behavior does not remit with primary ADHD therapy. 4 Several antipsychotic medications (e.g., risperidone) have been shown consistently to reduce aggressive behavior in children. 5, 6 However, controversy exists as to whether children with ADHD who exhibit serious aggression can be adequately managed with these antipsychotic medications. 7 The DSM-IV criteria for ADHD excluded pervasive developmental disorder (PDD). However, in DSM-5, PDD has been changed to autism spectrum disorder (ASD), and the coexistence of ASD and ADHD (ASD/ADHD) is now recognized. In a 2001 survey, 83% of children with PDD were also diagnosed with ADHD. 8 Similarly, in Japan, 67.9% of highfunctioning PDD children met the diagnostic criteria for ADHD. 9 Parent and teacher reports indicate that children with ASD/ADHD experience more difficulty in daily situations 10 and have greater psychopathology 11, 12 than those who have ASD or ADHD alone. The Autism Treatment Network database suggests that individuals who have comorbid ASD/ADHD tend to have poorer adaptive functioning and lower quality of life compared with those who have ASD alone. 13 In addition, children with ASD have a high rate of irritability and aggressive symptoms. Several previous studies have suggested that several risk markers could be identified for particular forms of challenging behavior in patients with ASD. Although previous research suggests that aggressive behaviors are more common in children with ASD than in other populations, [14] [15] [16] [17] [18] [19] prevalence estimates of aggressive behaviors in children with ASD vary widely according to age, IQ, sex, and ASD trait. Therefore, aggression might be influenced not only by ASD/ADHD symptoms, but also age, IQ, and several other factors. Additionally, maladaptive behaviors, including aggression, self-injury, and severe tantrums, are thought to cause families more stress than the core features of ASD alone. 20, 21 Taken together, findings indicate that ASD/ADHD is associated with aggression.
Risperidone and aripiprazole are atypical antipsychotic medications that have received approval by the US Food and Drug Administration for the treatment of irritability and agitation in children with ASD. Antipsychotic medications should not be used as first-line treatment of any indication without an appropriate initial evaluation and appropriate ongoing monitoring according to the 2013 guidelines issued by the American Psychiatric Association. Before resorting to antipsychotic medications, many evidence-based behavioral treatments, including training parents and social-skill training, are now available for children with emotional and behavioral disorders. 22 Because training-based treatments are at times ineffective or impractical, pharmacotherapy may be necessary. 23 Pharmacotherapy using antipsychotic medications thus presents a quick and affordable treatment option that may be implemented in daily medical practice. Therefore, clinicians often use antipsychotic medications to manage aggression in pediatric and adolescent patients with ASD/ADHD.
Although psychiatrists prescribe atypical antipsychotic medications to treat aggression in pediatric and adolescent ASD/ADHD patients in daily medical practice, little is known about how the efficacies of these treatments differ between patients with ASD/ADHD and those with only ADHD. No studies have reported how psychotropic medication affects aggression in pediatric and adolescent patients with ASD/ADHD in Japan. Therefore, we surveyed Japanese psychiatrists treating children and adolescents, and investigated their experiences in prescribing psychotropic medication to aggressive patients with ASD/ADHD. We hypothesized that: (i) there would be differences in prescriptions made by psychiatrists who routinely prescribe psychotropic medications for aggression in pediatric and adolescent patients with ASD/ADHD compared with those who do not; and (ii) results would delineate several factors important in the treatment of aggression in pediatric and adolescent patients with ASD/ADHD.
METHODS Participants
All participants were psychiatrists who treated children or adolescents and who were regular members of the Japanese Society for Child and Adolescent Psychiatry. A prospective questionnaire was mailed to 2001 psychiatrists and 571 (28.5%) responded. Eligibility criteria were as follows: (i) the respondent provided care to children aged <18 years; and (ii) the respondent fully completed the questionnaire. Four hundred and eighty-eight respondents (85.1%) met these eligibility criteria. Thus, the analyzed data came from 24.4% (488/2001) of psychiatrists who were approached. The questionnaire focused on respondents' experiences prescribing medication over a 1-month period for treating aggression in pediatric and adolescent patients with ADHD or ASD/ADHD. In the questionnaire, aggression was defined as any form of behavior with the goal of harming or injuring another living being who is motivated to avoid such treatment, regardless of frequency, intensity, and duration. 24 
Questionnaires
Respondents answered the following questions: We also collected baseline demographic data from each psychiatrist, including the number of years they had been practicing as a doctor.
The survey and a return-addressed envelope were mailed to all prospective respondents between April 2014 and July 2015. The questionnaire was anonymous and examined generic prescription and pharmacotherapy preferences regarding aggression in pediatric and adolescent ASD/ADHD patients. The Institutional Review Board at Nara Medical University approved the survey.
Statistical analyses
Means, SD, and percentages were used to describe the sample data. Variables included the following: (i) respondents' mean years as a practicing doctor; (ii) respondents' most commonly prescribed medication among the five provided in survey question #2; (iii) the relative effect of the medications for ASD/ADHD vs ADHD patients (superior, similar, inferior); and (iv) the factors affecting their decision to prescribe psychotropic medication to treat aggression in pediatric and adolescent ASD/ADHD patients (see survey question #4 above).
We used a multivariate logistic regression model to identify which of the following factors predicted the prescription of medication to treat aggression in patients with ASD/ADHD. Potential predictors were the age and sex of the psychiatrist, duration of practice, type of prescription, perceived benefit of treating patients with ASD/ADHD compared with that of treating patients with only ADHD, and several factors related to the patients (age, sex, FIQ > 70, residual symptoms of inattention, hyperactivity, or impulsivity, onset of adverse events after treatment with ADHD drugs, and whether the previous ADHD medication was sufficient). The predictors were identified using pharmacotherapeutic data related to treating aggression over a 1-month period. The sign of the multivariate logistic regression coefficient (log odds ratio) indicates the valence of the relation between pharmacotherapy and the independent variables. Additionally, variables were compared using χ 2 -tests. Odds ratios (OR) and 95% confidence intervals (CI) were used to describe the observed associations. The threshold for statistical significance was set at 0.05 and tests were two-tailed. We used PASW Statistics 18.0 J for Windows (SPSS, Tokyo, Japan) for the statistical analysis.
RESULTS

Respondent characteristics
Among the final sample (571 respondents), the mean duration of practice was 21.9 AE 10.2 years. Eighty-five percent of respondents (488/571) had prescribed medication for treating pediatric and adolescent ASD/ADHD. Among these respondents, 299 (61.3%) prescribed psychotropic medication to treat aggression in these patients and 185 did not (38.7%; Table 1 ). Those who did prescribe psychotropic medication were significantly older (P < 0.05) and had been in practice significantly longer (P < 0.01), although the differences were relatively small (about 2.5 years for both age and duration of practice). There was no difference in the sex of the psychiatrist between these two groups (χ 2 = 0.29, P = 0.53). The most commonly prescribed medication category was MPH (46.1%), followed by ATX (34.1%), antipsychotic medications (13.4%), antidepressant drugs (0.6%), and other medications (5.8%).
Predictors for using pharmacotherapy to treat aggression
Independent variables of duration of practice and residual symptoms of impulsivity significantly predicted the decision to prescribe medication for treating aggression (Table 2) . Respondents who prescribed psychotropic medication to treat aggression in these ASD/ADHD patients had been in practice significantly longer (OR, 1.055; 95%CI, 1.003-1.111; P = 0.038), and more frequently selected antipsychotic medications in treating aggression in such patients (χ 2 = 22.08; P < 0.01). In contrast, they prescribed ATX less frequently than those who prescribed psychotropic medication to treat aggression in ASD/ADHD patients. Additionally, residual impulsivity predicted prescription of medication in treating such patients (OR, 2.479; 95%CI, 1.045-5.885; P = 0.039). The respondents did not consider medication to benefit patients with ASD/ADHD more than those with only ADHD in terms of treating aggression (OR, 0.862; 95%CI, 0.684-1.087; P = 0.209).
Regarding respondents who prescribed psychotropic medication to patients with ASD/ADHD (n = 299), those who considered pharmacotherapy for aggression did not differ from those who did not in their recommendation for polypharmacy (χ 2 = 1.680, P = 0.200; Fig. 1 ) or in how many types of medication they prescribed (χ 2 = 1.060, P = 0.900).
DISCUSSION
To our knowledge, this article is the first to examine psychiatrists' experiences in prescribing psychotropic medications to treat aggression in pediatric and adolescent patients with ASD/ADHD. Our results showed that older psychiatrists more frequently opted for pharmacotherapy in these cases, although the difference in age was small (about 2.5 years). Additionally, those who prescribed psychotropic medications for treating aggression in patients with ASD/ADHD did not perceive any relative benefit for patients with ASD/ADHD over those with ADHD alone.
Based on evidence from several studies, 25, 26 antipsychotics are often prescribed to treat aggression in pediatric and adolescent ASD/ADHD patients. However, antipsychotic medications can be associated with metabolic syndrome, defined by a combination of central obesity, high blood pressure, low highdensity lipoprotein cholesterol, elevated triglycerides, and hyperglycemia. 27 Despite knowing the risk of these antipsychotic medications, their use in treating children in not only the USA but also Japan is quite high, mostly as off-label prescriptions. 28, 29 However, evidence has not yet been gathered on this in relation to pediatric or adolescent patients with ASD/ADHD in Japan. Therefore, more research into this topic is necessary.
In the present study, several key factors increased the odds of prescribing pharmacotherapy for treating aggression in these patients: one was the symptom of residual impulsivity. Some research indicates that children with ASD/ADHD experience limited therapeutic benefit when treated with MPH, particularly compared with expected outcomes based on MPH treatment of non-comorbid ADHD. [30] [31] [32] In contrast, ATX caused no significant symptom reduction in patients with severe autistic disorders who also had ADHD symptoms. 33 Because of the poor pharmacological effect on ADHD symptoms in pediatric and adolescent patients with ASD/ADHD, psychiatrists might prescribe many psychotropic medications for these patients. In addition, our questionnaire-based study found that a sufficient previous dose of medication for treating ADHD (MPH or ATX) had less effect on treating aggression in pediatric and adolescent patients with ASD/ADHD than in those with ADHD alone. Furthermore, the responders reported a similar effect for patients with ADHD/ASD as compared to those with ADHD alone in treating aggression. This finding might be based, at least partially, on the fact that medication for treating ADHD (MPH or ATX) more easily causes adverse effects in pediatric and adolescent patients with ASD/ADHD than in those with ADHD. Previous research has found that 18% of children with ASD/ADHD discontinued treatment due to adverse effects, particularly irritability, compared with only 1.4% of children with ADHD. 34 One investigation found that psychiatrists prescribed second-generation antipsychotic medications for children exhibiting aggression in the USA. 35 As mentioned above, however, antipsychotic medications are associated with metabolic syndromes. Greater knowledge regarding the use of psychotropic medications will allow psychiatrists to optimally balance the potential benefits and risks. In Japan, standard educational programs and practice guidelines that provide evidence-based support to psychiatrists for the prescribing of psychotropic medications have been lacking. Practice guidelines for clinical decision-making are needed to assist child and adolescent psychiatrists in Japan who prescribe psychotropic medications. Finally, we should notice that aggressive prescribing and the use of multiple medications may be clinically appropriate at times -especially for a high-risk population of those with ADHD/ASD and aggression. Moreover, even if psychiatrists have sufficient experience prescribing psychotropic medications in pediatric and adolescent patients with ASD/ADHD, we note that this could lead to polypharmacy or routine prescriptions.
The following limitations should be considered in interpreting the present findings. First, the response rate was relatively low (24.4%), and comparing respondents with non-respondents was not possible. This may have affected how well the target population was represented. Therefore, these findings cannot be generalized to every specialist in Japan. Second, we could not distinguish between aggression and irritability in the present study, making interpretation of some of the results difficult. Third, this study exclusively examined psychiatrists affiliated with the Japanese Society for Child and Adolescent Psychiatry. Therefore, the findings may not be generalizable to psychiatrists outside Japan. Moreover, the range of psychotropic medications is limited by regulatory agencies. At the time of survey, only the following three psychotropic medications had been approved in Japan: MPH and ATX for the treatment of children with ADHD, and pimozide for the treatment of behavioral problems in children with ASD or intellectual disability. Therefore, Japanese psychiatrists are prone to first prescribe MPH or ATX to treat ADHD, and then antipsychotic medications. Additionally, we did not examine each interclass of psychotropic medication category, or consider other psychotropic medication, such as first-generation antipsychotics, antiepileptic medications, mood stabilizers, or glutamatergic modulators. Nevertheless, the psychiatrists included in the present study were pediatric and adolescent specialists, and we consider these findings to be appropriate and sophisticated. Further, informed-consent procedures may have varied between psychiatrists, particularly regarding psychotropic medications not approved by the regulatory agency, due to the lack of standard educational programs for pediatric and adolescent psychiatrists in Japan.
Prescribing psychotropic medications in treating aggression in ASD/ADHD patients was related to several key variables. However, the respondents reported a similar effect for patients with ADHD/ ASD as compared with those with ADHD alone in treating aggression. Clinical trials should determine whether this perception has real clinical validity. The present study did not examine pharmacology preferences regarding all antipsychotic medications. Future research should therefore examine pharmacology preferences in prescribing antipsychotic medications for treating aggression in pediatric and adolescent patients with ASD/ADHD.
